Showing: 1 - 3 of 7 RESULTS
Banner News Niemann-Pick Type C News Research News

Zevra Therapeutics to Sell Priority-Review Voucher for $150 Million related to NPC drug approval

February 27, 2025 at 7:31 AM EST CELEBRATION, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) — Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that it has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease …

Announcements Banner News Niemann-Pick Type C News Research News

FDA Approves 2nd New Drug to Treat NPC

FDA Approves New Drug to Treat Niemann-Pick Disease, Type C | FDA For Immediate Release:September 24, 2024 Today, the U.S. Food and Drug Administration approved Aqneursa (levacetylleucine) for the treatment of neurological symptoms associated with Niemann-Pick disease type C (NPC) in adults and pediatric patients weighing at least 15 kilograms.  “This is the second treatment …